Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Amortization of Deferred Charges (2010 - 2017)

Opus Genetics (IRD) reported Amortization of Deferred Charges of $219577.0 for Q4 2017, down 34.07% on a QoQ basis from $333050.0 in Q2 2017.

Opus Genetics (IRD) has 6 years of Amortization of Deferred Charges data on file, last reported at $219577.0 in Q4 2017.

  • Quarterly Amortization of Deferred Charges changed N/A year-over-year to $219577.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $552627.0 (up 76.51% YoY) and the FY2017 annual result came in at $552627.0, up 76.51% from the prior year.
  • Amortization of Deferred Charges retreated to $219577.0 in Q4 2017 per IRD's latest filing, from $333050.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $333050.0 in Q2 2017 and bottomed at $91653.0 in Q4 2013.
  • The 4-year median for Amortization of Deferred Charges is $169887.0 (2016), against an average of $182300.1.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Opus Genetics 357.99 Mn 298.03 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 219,577.00
Dec 31, 2017 219,577.00
Jun 30, 2017 333,050.00
Jun 30, 2017 333,050.00
Sep 30, 2016 143,203.00
Sep 30, 2016 143,203.00
Mar 31, 2016 169,887.00
Mar 31, 2016 169,887.00
Mar 31, 2014 206,172.00
Mar 31, 2014 206,172.00
Dec 31, 2013 91,653.00
Dec 31, 2013 91,653.00
Sep 30, 2013 112,559.00
Sep 30, 2013 112,559.00
Mar 31, 2011 97,667.00
Mar 31, 2011 97,667.00
Jun 30, 2010 180,080.00
Jun 30, 2010 180,080.00